M&A Deal Summary

Envista Acquires Osteogenics

On May 17, 2022, Envista acquired medical products company Osteogenics

Acquisition Highlights
  • This is Envista’s 2nd transaction in the Medical Products sector.
  • This is Envista’s 2nd transaction in the United States.
  • This is Envista’s 1st transaction in Texas.

M&A Deal Summary

Date 2022-05-17
Target Osteogenics
Sector Medical Products
Buyer(s) Envista
Deal Type Add-on Acquisition

Target

Osteogenics

Lubbock, Texas, United States
Osteogenics is a developer of regenerative solutions for periodontists, oral & maxillofacial surgeons, and clinicians involved in implant dentistry throughout the world. Osteogenics is based in Lubbock, Texas.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Envista

Brea, California, United States

Category Company
Founded 2018
Sector Medical Products
Employees12,800
Revenue 2.6B USD (2023)
DESCRIPTION

Envista is a global family of three operating companies and more than 30 dental brands. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic. Envista was founded in 2018 and is based in Brea, California.


DEAL STATS #
Overall 2 of 2
Sector (Medical Products) 2 of 2
Type (Add-on Acquisition) 1 of 1
State (Texas) 1 of 1
Country (United States) 2 of 2
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-12-22 Carestream Dental s Intra-Oral Scanner Business

Atlanta, Georgia, United States

Carestream Dental's Intra-Oral Scanner (IOS) Business is composed of Carestream Dental’s intraoral scanner equipment (CS 3600, CS 3700, and CS 3800) and related software.

Buy $600M